Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Timothy Cloughesy is the Director of the NeuroOncology Program and a Professor at the Ronald Reagan UCLA Medical Center in the United States. His research focuses on the treatment and assessment of glioblastoma and related conditions, as evidenced by his recent articles exploring novel therapies, imaging techniques, and clinical trial endpoints. He is also involved in advancing response assessment criteria in neuro-oncology to improve patient outcomes.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (18)

Martin van den Bent

Erasmus University Rotterdam

NETHERLANDS

Timothy Cloughesy

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective

Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

“Synthetic” DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma

A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults

Pseudo-Resting-State Functional MRI Derived from Dynamic Susceptibility Contrast Perfusion MRI Can Predict Cognitive Impairment in Glioma

ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma

Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials

Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1

Preferential tumor localization in relation to 18F-FDOPA uptake for lower‐grade gliomas

Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas

Collaborators (18)

Martin van den Bent

Phioanh Nghiemphu

Timothy Kaufmann

Jerrold Boxerman

Daniel Barboriak

Steffen Ventz

Alphonsus Ng

Hiroyuki Tatekawa

Kathleen Van Dyk

Linda Liau

Jingwen Yao

Yue Lu

Whitney Pope

Benjamin M Ellingson

Richard Everson

Johan Pallud

Serendipity Rinonos

Robert Prins

Make your next move.